Enfan Zhang
- Cancer Research top 10%
- Hematology top 5%
- Multiple Myeloma Research and Treatments 22
- Acute Myeloid Leukemia Research 5
- Immunology top 10%
- Immune cells in cancer 7
- Molecular Biology top 10%
- Ubiquitin and proteasome pathways 12
- Protein Degradation and Inhibitors 12
- Histone Deacetylase Inhibitors Research 7
- Oncology top 10%
- Peptidase Inhibition and Analysis 9
- Chemokine receptors and signaling 5
- Co-authors
- Zhen CaiJingsong HeHaimeng YanJianwei QuWen CaoRuyi XuHuiyao GuYang Liu
- Cited by
- Cancer ResearchHematologyImmunology
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Enfan Zhang
53 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 105
- Cancer Research 301
- Hematology 211
- Immunology 361
- Molecular Biology 813
- Oncology 287
Countries citing papers authored by Enfan Zhang
This map shows the geographic impact of Enfan Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enfan Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enfan Zhang more than expected).
Fields of papers citing papers by Enfan Zhang
This network shows the impact of papers produced by Enfan Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enfan Zhang. The network helps show where Enfan Zhang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Enfan Zhang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 19 | |
| 3 | 2024 | 3 | |
| 4 | 2023 | 12 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 5 | |
| 8 | 2022 | 5 | |
| 9 | 2022 | 7 | |
| 10 | 2021 | 26 | |
| 11 | 2021 | 15 | |
| 12 | Metabolic reprogramming in macrophage responsesbreakdown → | 2021 | 386 |
| 13 | 2020 | 35 | |
| 14 | 2020 | 7 | |
| 15 | 2019 | 85 | |
| 16 | 2019 | 41 | |
| 17 | 2019 | 22 | |
| 18 | 2018 | 22 | |
| 19 | 2018 | 21 | |
| 20 | 2016 | 30 |
About Enfan Zhang
Enfan Zhang is a scholar working on Hematology, Oncology and Immunology, having authored 58 papers that have together received 1.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (22 papers), Ubiquitin and proteasome pathways (12 papers), Protein Degradation and Inhibitors (12 papers), Peptidase Inhibition and Analysis (9 papers), Histone Deacetylase Inhibitors Research (7 papers), Immune cells in cancer (7 papers), Acute Myeloid Leukemia Research (5 papers) and Chemokine receptors and signaling (5 papers). The work is most often cited by research in Cancer Research (301 citations), Hematology (211 citations) and Immunology (361 citations). Enfan Zhang has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Zhen Cai, Jingsong He, Haimeng Yan, Jianwei Qu, Wen Cao, Ruyi Xu, Huiyao Gu, Yang Liu, Xi Huang and Xi Huang. Their work appears in journals such as Blood, Cancer Research and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.